Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Automatic Data Processing Inc (ADP) vs Pfizer Inc (PFE) Price & Performance

Automatic Data Processing Inc
Pfizer Inc

Price performance

Price movement over the last 24 hours

Key statistics

Automatic Data Processing Inc vs Pfizer Inc — how do they compare? Automatic Data Processing Inc trades at $241.91 (market cap $98.17B), while Pfizer Inc trades at $24.24 (market cap $137.19B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (7.15%). Which is the better fit depends on your goals.

ADPPFE
Market Cap
$98.17B$137.19B
Sector
IndustrialsHealth
52-Week High
$310.94$28.56
52-Week Low
$188.79$23.29
Enterprise Value
$99.24B$187.84B
Dividend Yield
2.77%7.15%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Automatic Data Processing Inc

ADP trades at $245.60, up 1.37% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Revenue grew to $20.56 billion in 2025, with a net income margin of 20.12%. Analyst sentiment is mixed, with a consensus hold rating but a technical outlook suggesting strength. The company maintains strong profitability metrics and recently announced a dividend payment.

Outlook remains stable with projected revenue growth to $21.6 billion in 2026. Risks include competitive pressures and economic sensitivity. Opportunities lie in AI integration and margin expansion. The stock offers value through dividends and steady performance, though valuation multiples are elevated relative to historical averages.

Pfizer Inc

Pfizer (PFE) trades at $23.72, down 2.47% on the day, with a bearish technical signal from moving averages but recent earnings beats. The stock has a P/E of 18.11 and net income margin of 11.83%, supported by strong cash flow from operations of $11.70B in 2025. Recent news highlights pipeline progress in obesity and oncology, with dividends of $0.43 paid semi-annually.

The outlook is mixed: analyst consensus is a 'Hold' with a $27.63 price target, implying potential upside, but risks include patent cliffs and competitive pressures. Revenue has declined from pandemic peaks, yet cost controls sustain profitability. Investors may find value if pipeline catalysts materialize, though near-term volatility persists.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Automatic Data Processing Inc

ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.

Read more on ADP

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE